Educational Disclaimer: This article is provided for informational purposes only and does not constitute medical advice, diagnosis, or treatment. TMS for OCD requires a comprehensive clinical evaluation to determine appropriateness for each individual. Only a qualified clinician can determine whether TMS is an appropriate treatment option for you. Please consult your mental health provider before making any treatment decisions.
Contents
- What Is OCD?
- How Does TMS Treat OCD? The Brain Science
- Which TMS Device Is FDA-Cleared for OCD?
- What to Expect During TMS Treatment for OCD
- How Effective Is TMS for OCD? What Research Shows
- TMS for OCD vs. Other Treatments
- Who Qualifies for TMS for OCD?
- Frequently Asked Questions
TMS for OCD represents a meaningful advance in treatment options for one of the most challenging psychiatric conditions. Transcranial magnetic stimulation (TMS) is now FDA-cleared for the treatment of obsessive-compulsive disorder – specifically, the BrainsWay deep TMS (dTMS) system using its H7 coil, which received FDA De Novo clearance in 2018. For people with OCD who have not achieved adequate relief from medication and therapy alone, dTMS offers a non-invasive, non-systemic treatment approach that targets the neural circuits underlying OCD directly. No anesthesia is required, there is no systemic medication exposure, and patients can return to daily activities immediately after each session.
What Is OCD?
Obsessive-compulsive disorder (OCD) is a serious, often debilitating psychiatric condition characterized by two core features: obsessions and compulsions.
Obsessions are intrusive, unwanted thoughts, images, or urges that cause marked anxiety or distress. They are persistent and feel difficult or impossible to ignore. Common obsession themes include contamination fears, fears of harming oneself or others, symmetry and exactness concerns, unwanted sexual or religious thoughts, and fears about making catastrophic mistakes.
Compulsions are repetitive behaviors or mental acts performed in response to obsessions – an attempt to neutralize or reduce the anxiety the obsession generates. Common compulsions include washing and cleaning, checking, ordering and arranging, mental reviewing or reassurance-seeking, and counting. The relief from compulsions is temporary; the obsessions return, often with greater intensity, creating a self-reinforcing cycle.
According to the DSM-5, an OCD diagnosis requires that obsessions and/or compulsions are time-consuming (more than one hour per day), cause significant distress, and meaningfully impair daily functioning. OCD affects approximately 2–3% of the general population and is often misunderstood. It is not “being a neat freak” or “being a little OCD.” For many people who live with it, OCD is a serious condition that consumes hours of each day, interferes with relationships and work, and may persist for years or decades if untreated or inadequately treated.
How Does TMS Treat OCD? The Brain Science
Understanding why TMS may help with OCD requires understanding the neuroscience of OCD itself. OCD involves dysregulation in the cortico-striato-thalamo-cortical (CSTC) circuit – a loop connecting the cortex, striatum (including the caudate nucleus), thalamus, and back to the cortex. In OCD, this circuit functions like a car alarm that won’t turn off: it generates an escalating “something is wrong” signal that drives repetitive, compulsive responding.
Key nodes in this circuit include the anterior cingulate cortex (ACC) – involved in error detection and conflict monitoring – and the supplementary motor area (SMA), which plays a role in inhibiting unwanted actions. Neuroimaging research has consistently shown hyperactivity in these regions in people with OCD, and normalization of activity in these regions has been associated with treatment response.
The BrainsWay H7 coil is specifically engineered to reach these deeper cortical and subcortical structures. By delivering repetitive magnetic pulses to the ACC and SMA, dTMS modulates activity in the CSTC circuit – reducing the hyperactivation that drives obsessions and compulsions. The treatment does not eliminate OCD’s neural circuitry; it changes how that circuitry functions, reducing the intensity of the signal that compulsions are attempting to address.
Which TMS Device Is FDA-Cleared for OCD?
FDA Accuracy Note: It is critical to use precise language when discussing FDA regulatory status. “FDA-approved” and “FDA-cleared” have different regulatory meanings. The BrainsWay dTMS H7 system received FDA De Novo clearance for OCD in 2018 – not “FDA approval.” Standard figure-8 TMS coils (used for depression) are not FDA-cleared for OCD. These distinctions matter for accuracy and for patients making informed treatment decisions.
| Device / System | Regulatory Status for OCD | Notes |
| BrainsWay dTMS with H7 coil | FDA De Novo clearance (2018) | The only TMS system specifically FDA-cleared for OCD. Uses deep TMS technology to reach the ACC/SMA. |
| Standard figure-8 TMS coil (various manufacturers) | FDA-cleared for MDD; NOT cleared for OCD | Some clinicians use standard TMS off-label for OCD. This is legal but does not carry the same regulatory backing as the BrainsWay H7 system for this indication. |
| BrainsWay dTMS with H1 coil | FDA-cleared for MDD and smoking cessation; NOT for OCD | Different coil geometry; does not target OCD circuits in the same way as the H7. |
When evaluating TMS providers for OCD treatment, patients and families should confirm that the provider uses the BrainsWay H7 system – the only configuration with FDA De Novo clearance specifically for OCD. This distinction reflects genuine differences in coil design, stimulation depth, and the evidence base supporting each system for this specific indication.
What to Expect During TMS Treatment for OCD
TMS treatment for OCD follows a structured protocol that differs in one important respect from TMS treatment for depression: the symptom provocation component.
Initial Assessment
Before beginning treatment, a clinical evaluation confirms the OCD diagnosis, reviews prior treatment history (medications, therapy), assesses for contraindications (metal implants near the head, seizure history, pregnancy), and establishes a baseline symptom severity measurement – typically using the Yale-Brown Obsessive Compulsive Scale (Y-BOCS).
Symptom Provocation Before Stimulation
A distinctive feature of the FDA-cleared OCD protocol is a brief, clinician-guided symptom provocation component immediately before each TMS session. Before the magnetic stimulation begins, the clinician briefly and gently engages the patient with content related to their OCD – a contamination cue, a checking scenario, or other individually tailored exposure – for approximately 30 seconds. This is designed to engage the specific neural circuits involved in the patient’s OCD at the time of stimulation, so that TMS is applied to an actively engaged circuit rather than a resting one.
This provocation is brief, carefully calibrated, and clinician-guided. It is not a prolonged exposure exercise. For patients unfamiliar with this component, it can sound alarming – but in practice, it involves minimal, controlled, transient discomfort, and is immediately followed by the TMS session itself.
The TMS Session
- The patient is seated comfortably; no sedation or anesthesia is required
- The H7 coil is positioned over the relevant scalp region
- Magnetic pulses are delivered in a pattern determined by the treatment protocol
- Each session typically lasts approximately 20 minutes
- The sensation is commonly described as a tapping or clicking feeling on the scalp; the most common side effect is a mild scalp discomfort or headache that typically resolves shortly after the session
Treatment Course
The clinical trial protocol that supported FDA clearance involved 29 sessions over approximately 6 weeks – a treatment course mirroring the structure of the pivotal trial (Carmi et al., 2019). Patients can drive themselves to and from sessions and return to normal activities immediately afterward. There is no recovery period.
How Effective Is TMS for OCD? What Research Shows
The pivotal clinical trial supporting FDA clearance for TMS for OCD was published by Carmi and colleagues in 2019 in the American Journal of Psychiatry. In this randomized, double-blind, sham-controlled multicenter trial:
- Patients who received active dTMS showed significantly greater reduction in Y-BOCS scores compared to those who received sham (inactive) stimulation
- Response rates (defined as at least 30% reduction in Y-BOCS score) were meaningfully higher in the active treatment group
- The treatment was well tolerated, with the most common adverse event being scalp discomfort at the stimulation site
It is important to contextualize these findings honestly. TMS for OCD is not universally effective – response rates are meaningful but not universal, and individual outcomes vary. TMS is not intended as a standalone treatment for OCD; it is most effective when combined with ongoing psychotherapy, particularly Exposure and Response Prevention (ERP). The International OCD Foundation (IOCDF) notes that TMS represents a significant treatment advance for those with inadequate response to first-line approaches, while emphasizing that ERP remains the behavioral treatment with the strongest evidence base.
TMS for OCD vs. Other Treatments
| Treatment | Role in OCD Care | How It Relates to TMS |
| Exposure and Response Prevention (ERP) | Gold-standard behavioral treatment for OCD; strongest evidence base | TMS works as an adjunct to ERP, not a replacement. The most robust outcomes are achieved when both are used together. |
| SSRIs (e.g., fluvoxamine, sertraline, fluoxetine) | First-line pharmacological treatment; higher therapeutic doses typically needed for OCD than for depression | TMS is generally indicated for those with partial or inadequate response to at least one adequate SSRI trial |
| Cognitive Behavioral Therapy (CBT) with ERP | The behavioral component of CBT for OCD is ERP; combined approach is evidence-based | Internal link: cognitive behavioral therapy at Synchrony Brain Health |
| Spravato / Ketamine | Primarily indicated for treatment-resistant depression (TRD); some individuals with OCD have co-occurring TRD | For individuals with OCD and co-occurring TRD, Spravato/ketamine may be relevant to the broader treatment plan |
The OCD treatment landscape has evolved significantly. The standard of care involves ERP as the behavioral backbone, SSRIs as first-line pharmacotherapy, and – for those with inadequate response to these approaches – TMS as an evidence-based adjunctive option. The combination of dTMS and ERP has shown synergistic effects: TMS may reduce the intensity of OCD symptoms enough to make ERP more tolerable and effective for patients who previously found exposure exercises too distressing to complete.
Who Qualifies for TMS for OCD?
TMS for OCD is not appropriate for everyone with OCD – it requires clinical evaluation to determine suitability. General qualifying criteria typically include:
- A confirmed diagnosis of OCD by a qualified clinician
- Inadequate response to at least one adequate trial of an SSRI (at an appropriate dose for a sufficient duration) and a course of ERP therapy
- No absolute contraindications: metallic implants near the head (cochlear implants, certain aneurysm clips, deep brain stimulators), active seizure disorder, or pregnancy
- Ability to participate in the treatment protocol, including the symptom provocation component
A thorough clinical evaluation at Synchrony Brain Health’s dTMS program determines whether dTMS is an appropriate treatment option and, if so, develops an integrated treatment plan that incorporates TMS alongside the psychotherapy and medication management components most likely to support optimal outcomes.
Frequently Asked Questions
Is TMS FDA-approved or just FDA-cleared for OCD?
TMS for OCD is FDA-cleared – not FDA-approved. These are distinct regulatory designations. Specifically, the BrainsWay deep TMS system with its H7 coil received FDA De Novo clearance for OCD in 2018 through a regulatory pathway for novel, low-to-moderate-risk devices. “FDA-approved” and “FDA-cleared” are sometimes used interchangeably in popular usage, but they differ technically. For OCD, the accurate language is “FDA De Novo cleared” or simply “FDA-cleared.” Only the BrainsWay H7 system carries this clearance specifically for OCD.
How many TMS sessions are needed for OCD?
The clinical trial protocol that supported FDA clearance involved 29 sessions delivered over approximately 6 weeks. Individual treatment courses may be adjusted based on clinical response and provider recommendation, but the 29-session, 6-week protocol is the evidence-based standard for dTMS treatment of OCD using the BrainsWay H7 system.
Does TMS for OCD hurt?
TMS for OCD is generally well tolerated. The most commonly reported sensation during treatment is a tapping or clicking feeling at the scalp at the site of stimulation. Mild scalp discomfort or headache following a session is the most common side effect and typically resolves within a few hours. TMS does not require anesthesia and does not involve pain in the conventional sense. The brief symptom provocation before each session involves transient, mild OCD-related discomfort, which patients are prepared for and which resolves quickly.
Can TMS be used with medication for OCD?
Yes. TMS for OCD is typically used in conjunction with ongoing medication (usually an SSRI) and psychotherapy (ERP), not instead of them. The most effective outcomes appear to occur when TMS is part of an integrated treatment plan rather than a standalone intervention. Decisions about medication adjustments during or after TMS should be made in close consultation with a prescribing clinician.
Synchrony Brain Health offers dTMS for qualifying individuals with OCD and other treatment-resistant conditions. If you or someone you care about has not found adequate relief from medication and therapy alone, a clinical evaluation can clarify whether dTMS may be appropriate. The team at Synchrony Brain Health in Chicago includes clinicians experienced in the assessment and treatment of OCD using integrated, evidence-based approaches.
Citations: Carmi, L., et al. (2019). Efficacy and safety of deep transcranial magnetic stimulation for obsessive-compulsive disorder: a prospective multicenter randomized double-blind placebo-controlled trial. American Journal of Psychiatry, 176(11), 931–938. U.S. Food and Drug Administration. (2018). De Novo classification request for BrainsWay deep TMS system for OCD. FDA DEN170106. International OCD Foundation (IOCDF). (2022). TMS for OCD. Retrieved from iocdf.org. American Psychiatric Association. (2013). Diagnostic and Statistical Manual of Mental Disorders (5th ed.). Rotge, J.Y., et al. (2010). Provocation of obsessive-compulsive symptoms: a quantitative voxel-based meta-analysis of functional neuroimaging studies. Journal of Psychiatry and Neuroscience, 35(5), 297–306. Greenberg, B.D., et al. (2010). Deep brain stimulation of the ventral internal capsule/ventral striatum for obsessive-compulsive disorder. Molecular Psychiatry, 15(1), 64–79.
